Wednesday, September 26, 2012

Xalkori for lung cancer patients

 People with non-small cell lung cancer that have the ALK genetic mutation have a new option for treatment called XALKORI (crizotinib).  It is a very effective oral drug with the potential to give an average of 8 months of remission.  This is exciting news for this type of cancer. Ask your oncologist if your tumor has been tested for the ALK mutation.


No comments:

Post a Comment